Christian, Bradley THanden, Benjamin LHead, ElizabethMapstone, Mark
Alzheimer's disease (AD) is a major public health crisis for our aging population. People with Down Syndrome (DS) are at high risk for AD and because of their unique biology and provide an unparalleled opportunity to develop biomarkers of preclinical AD. Reliable biomarkers of preclinical AD will enable new options for intervention and promote health for people with DS and in the general population.
Down Syndrome Publications
Alzheimer's & dementia : the journal of the Alzheimer's Association2021
Neurobiology of aging2021